You are here

Advertising

Timing of Cord Clamping: A critical issue for major medical centers

December 2018
Norman Ende, MD

The following article is a contribution by Dr. Norman Ende and does not represent a policy position of Parent's Guide to Cord Blood Foundation.

Norman Ende, MD, CAPT MC USNR (Ret)Recently, Parent’s Guide to Cord Blood Foundation released a brochure on the time of clamping of the umbilical cord after the birth of the baby. This brochure is given to pregnant women and suggests clamping in the range of 30-60 seconds (quoting American College of Obstetrics Gynecology or ACOG) for full term babies.

Since the early beginning of cord blood banking there has been controversy over the appropriate time of clamping the umbilical cord after the birth of the infant. Some believed the cord should only be clamped after it stops pulsating (approximately 3 minutes), while others believed you should clamp the cord immediately (within seconds of birth) so the maximum amount of cord blood stem cells for transplantation may be obtained.

We believe that clamping the cord immediately is both morally and medically wrong. This method takes blood away from the infant. There is a concern that it could have a long-term unknown negative effect on the infant donor. For eons of time, this blood has gone back into the baby.

From the early 1990’s until recently, major medical centers performed cord blood collection after immediate clamping. These institutions should have records of the babies from which the cord blood was collected with immediate clamping. It is their moral and medical responsibility to review these records and investigate what has happened to these infant donors. Did they develop diabetes, autism, etc.? It is incumbent on these medical institutions to review the health history of these donors and conduct a retrospective analysis for any morbidity that correlates with immediate cord clamping. It has been over 25 years since those infants had immediate clamping, and this may not be long-term, but could be indicative of a trend in morbidity.

We believe this is an emergency situation. It is incumbent on the medical institutions that delivered babies with immediate cord clamping to review their records and attempt to evaluate the morbidity of those infant donors.

Doctors Milton and Norman Ende, photo published by University of Richmond MagazineBrothers Milton and Norman Ende both went to medical school at the Medical College of Virginia in Richmond1. In 1966 Dr. Milton Ende pioneered the first published case of cord blood as a therapy for cancer2. In 1972 both brothers published the first attempt to give a cord blood transplant to a cancer patient3. The Ende brothers are often overlooked in official histories of cord blood transplantation because they did not use immune suppression before treating patients with cord blood, yet their publications demonstrated transient efficacy of cord blood alone. They called the stem cells in cord blood “Berashis” cells, after the Hebrew word for “Genesis”4.  Dr. Milton Ende spent most of his career as a primary care doctor in Petersburg Virginia5, while Dr. Norman Ende was a pathologist on the faculty of the University of Medicine and Dentistry of New Jersey (UMDNJ). Dr. Norman Ende and colleagues performed a series of studies that examined how cord blood infusions altered the course of various disease models in mice6-8. Several papers explored the effects of cord blood infusions on mouse models of Type 1 and Type 2 diabetes9,10. Dr. Norman Ende and UMDNJ faculty member Alluru Reddi, PhD MD, a nephrologist who specializes in the treatment of diabetic microvascular complications, hypothesized that cord blood transfusions might protect low birth weight newborns from the development of type 2 diabetes later in life11,12. Dr. Norman Ende is now 94 years old and mostly retired, but he still actively follows news related to potential applications of cord blood. A full list of his publications can be found on his website, NormanEndeMD.com.

References

  1. Karl Rhodes. University of Richmond Magazine. Joined at the Cord. Winter 2005
  2. Ende M. Lymphangiosarcoma. Report of A Case Pac. Med. & Surg. 1966; (March-April):80-82
  3. Ende M. & Ende N. Hematopoietic Transplantation By Means Of Fetal (Cord) Blood. A New Method.  Virginia Medical Monthly 1972; 99(3):276-80
  4. Ende N. The Berashis cell: a review--is it similar to the embryonic stem cell? Journal of Medicine. 2000; 31(3-4):113-30.
  5. Obituary of Milton Ende. Published in The Progress-Index June 29, 2007.
  6. Ende N, Weinstein F, Chen R, Ende M. Human umbilical cord blood effect on sod mice (amyotrophic lateral sclerosis). Life Sciences 2000; 67(1):53-59
  7. Ende N, Chen R. Human umbilical cord blood cells ameliorate Huntington's disease in transgenic mice. Journal of Medicine 2001; 32(3-4):231-240
  8. Ende N, Chen R, Ende-Harris D.  Human umbilical cord blood cells ameliorate Alzheimer's disease in transgenic mice. Journal of Medicine 2001; 32(3-4):241-247
  9. Ende N, Chen R, Mack R. NOD/LtJ type I diabetes in mice and the effect of stem cells (Berashis) derived from human umbilical cord blood. Journal of Medicine 2002; 33(1-4):181-187
  10. Ende N, Chen R, Reddi AS. Transplantation of human umbilical cord blood cells improves glycemia and glomerular hypertrophy in type 2 diabetic mice. Biochemical and Biophysical Research Communications. 2004; 321(1):168-171
  11. Mi D, Fang H, Zhao Y, Zhong L. Birth weight and type 2 diabetes: A meta-analysis. Exp Ther Med. 2017; 14(6): 5313–5320.
  12. Ende N. & Reddi AS. Administration of human umbilical cord blood to low birth weight infants may prevent the subsequent development of type 2 diabetes. Medical Hypotheses 2006; 66(6):1157-1160